Italia markets open in 1 hour 30 minutes

Zealand Pharma A/S (0NZU.IL)

IOB - IOB Prezzo differito. Valuta in DKK.
Aggiungi a portafoglio
138,95+1,85 (+1,35%)
Alla chiusura: 06:59PM GMT
Schermo intero
Chiusura precedente137,10
Aperto141,50
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno139,40 - 143,80
Intervallo di 52 settimane129,30 - 237,40
Volume11.853
Media Volume11.219
Capitalizzazione6,034B
Beta (5 anni mensile)1,07
Rapporto PE (ttm)N/D
EPS (ttm)-26,50
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021

    Company announcement – No. 73 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: T

  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at November 30, 2021

    Company announcement – No. 72 / 2021 Total number of shares and voting rights in Zealand Pharma at November 30, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the

  • GlobeNewswire

    Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021

    Company announcement – No. 71 / 2021 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: Followi